PulsePoint Launches HCP2DTC Influence — Real‑Time Physician Data for DTC Health Campaigns, a new platform that fuses physician intelligence with direct‑to‑consumer advertising, promising pharma brands a unified way to target patients and prescribers simultaneously.
What PulsePoint Unveiled
Newark‑based PulsePoint announced the rollout of HCP2DTC Influence™, the first feature of its emerging “connected operating system” for health marketing. The solution lets pharmaceutical marketers pull first‑party physician prescribing data into DTC media plans, adjusting creative delivery on the fly as doctors’ prescribing patterns shift. In the launch announcement, PulsePoint highlighted early tests that cut cost‑per‑new‑prescription by up to 50 % while boosting new patient starts.
How the Technology Works
At its core, HCP2DTC Influence leverages PulsePoint’s proprietary first‑party HCP data foundation. The platform ingests anonymized prescribing signals, digital health engagement metrics, and brand interaction histories, then maps those signals to the consumer audiences a campaign is trying to reach. When a physician who frequently prescribes a brand’s therapy appears in a patient’s media consumption path, the system can prioritize that brand’s DTC creative, increase frequency, or swap in a different message—all in real time and without manual intervention.
The engine runs across programmatic channels—display, video, connected TV, and OTT—so adjustments cascade through a brand’s entire media stack. Because the data never leaves PulsePoint’s secure environment, the solution remains compliant with HIPAA and emerging privacy standards, a crucial differentiator in an industry where third‑party data is increasingly restricted.
Why It Matters to Health Marketers
Historically, pharma campaigns have operated in two silos: physician‑focused “HCP” outreach and consumer‑focused “DTC” advertising. Brands invest heavily in each, yet the intelligence generated on the HCP side rarely informs DTC media buying. This disconnect can result in wasted ad spend—patients may see a brand’s message but end up consulting a competitor’s physician, eroding conversion rates.
By marrying the two data streams, HCP2DTC Influence promises a more efficient funnel. According to a recent Gartner forecast, 70 % of pharmaceutical marketers will adopt integrated HCP‑DTC platforms by 2027, seeking to reduce acquisition costs and improve ROI. For enterprise marketing teams, the technology translates into a single dashboard for budget allocation, performance measurement, and compliance reporting, reducing the need for separate analytics stacks.
Competitive Landscape
PulsePoint is not the first to experiment with physician data in digital ads, but its first‑party approach sets it apart from rivals that rely on third‑party data aggregators or limited API feeds. Companies such as Veeva Systems and IQVIA have launched data services aimed at the same market, yet they typically require manual data pulls and lack real‑time activation. In contrast, HCP2DTC Influence offers automated, low‑latency adjustments comparable to what leading ad tech platforms like The Trade Desk provide for generic retail audiences.
Microsoft’s Azure Health Data Services and Google Cloud’s Healthcare API are expanding into health data integration, but they focus on clinical data exchange rather than marketing activation. PulsePoint’s niche—combining HCP prescribing signals with DTC media buying—fills a gap that larger cloud providers have not yet targeted.
Implications for Enterprise Teams
For large pharma and biotech firms, the platform could reshape media planning cycles. Instead of quarterly media buys based on static audience segments, marketers can now adopt a continuous optimization model, akin to the programmatic buying loops used in e‑commerce. The result is a tighter alignment between sales force efforts and digital spend, potentially shortening the sales cycle.
From an operational standpoint, the solution also simplifies compliance workflows. Because all physician data remains within PulsePoint’s controlled environment, legal teams can audit usage without negotiating multiple data‑sharing agreements. This could lower the barrier to adopting advanced AI‑enabled targeting, a trend highlighted in a recent Forrester study that linked AI‑enabled media optimization to a 30 % reduction in cost‑per‑acquisition for health brands.
Market Landscape
The health‑tech advertising market is at a crossroads. As privacy regulations tighten—e.g., the EU’s ePrivacy Regulation and the U.S. state‑level health data laws—reliance on third‑party cookies and data brokers is waning. Brands are turning to first‑party data strategies, and PulsePoint’s model is a textbook example of that shift.
Simultaneously, the rise of connected TV and OTT platforms has expanded the inventory where health messages can appear, but it has also fragmented measurement. Integrated solutions that can tie a physician’s prescribing event to a consumer’s ad impression are becoming a competitive advantage. PulsePoint’s partnership ecosystem already includes major DSPs and SSPs, and its API can feed data into Adobe Experience Cloud, Salesforce Marketing Cloud, and Amazon Advertising, enabling cross‑platform orchestration.
Top Insights
- Unified Funnel: HCP2DTC Influence bridges the traditional HCP‑DTC divide, allowing real‑time adjustments that can cut acquisition costs by up to 50 %.
- First‑Party Edge: By keeping physician data in‑house, PulsePoint sidesteps privacy roadblocks that hamper third‑party data vendors.
- Enterprise‑Ready: The platform integrates with Adobe, Salesforce, and Amazon ad stacks, offering a single compliance‑friendly dashboard for large health marketers.
- Competitive Gap: While Veeva and IQVIA provide data, they lack the automated, real‑time activation that PulsePoint delivers across programmatic channels.
- Market Momentum: Gartner predicts 70 % of pharma marketers will adopt integrated HCP‑DTC solutions by 2027, signaling rapid industry adoption.
Get in touch with our Adtech experts
